Consensus guidelines regarding breast conservation treatment for ER/PR positive DCIS involve adjuvant ipsilateral whole breast radiation therapy followed by the option of endocrine therapy with tamoxifen or an aromatase inhibitor in postmenopausal patients [9, 10]. Here, CYP19A1 is linked to ductal breast carcinoma in situ.